Overview

Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5

Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this project is to study the efficacy of three candidate molecules (Xenbilox, Tahor and Resveratrol) in order to decrease the production of oxysterols by reducing the synthesis of cholesterol and/or regulate the production of bile acids and/or enabling neuroprotective action within the motor neuron.
Phase:
Phase 2
Details
Lead Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France
Treatments:
Atorvastatin
Atorvastatin Calcium
Chenodeoxycholic Acid
Resveratrol